Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05608044 · ClinicalTrials.gov registry record · Phase 2

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

A Phase 2 study of Metastatic Colorectal Cancer, sponsored by Agenus.

Active
Registry status
Phase 2
Development phase
234
Enrollment target
20
Study locations

NCT05608044 is a Phase 2 study of Metastatic Colorectal Cancer that is active but no longer recruiting, run by Agenus. The registered enrollment target is 234 participants, above the 181-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05608044, a Phase 2 study of Metastatic Colorectal Cancer, is active but no longer recruiting, sponsored by Agenus.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
234 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.

Conditions Studied

Metastatic Colorectal Cancer

Interventions

  • DRUG Standard of Care
  • DRUG Balstilimab
  • DRUG Botensilimab

Study Locations (20)

New York

  • Weill Cornell Medicine - New York
  • Mount Sinai Hospital - New York - New York
  • Memorial Sloan Kettering - New York

California

  • City of Hope National Medical Center - Duarte
  • Keck School of Medicine of the University of Southern California - Los Angeles

Colorado

  • Rocky Mountain Cancer Center - Aurora - Aurora
  • University of Colorado - Denver

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Oregon

  • Earle A. Chiles Research Institute - Robert W. Franz Cancer Center - Providence Cancer Institute - Portland
  • Oregon Health & Science University (OHSU) - Portland

Tennessee

  • Tennessee Oncology Nashville (Sarah Cannon) - Nashville
  • Vanderbilt University School of Medicine - Nashville

Arizona

  • HonorHealth Research Institute - Scottsdale

Delaware

  • Medical Oncology Hematology Consultants - Newark

Trial Details

FieldValue
Enrollment Target 234 participants
Start Date 2022-11-30
Est. Completion 2029-09
Phase Phase 2

Sponsor

Agenus

24 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05608044

The ClinicalTrials.gov registry entry for NCT05608044 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (29% higher). The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.

NCT05608044 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT05608044 about?

NCT05608044 is a clinical study titled "A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer". This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.

What is the current status of trial NCT05608044?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2022-11-30. Estimated completion is 2029-09.

What conditions does trial NCT05608044 study?

This clinical trial studies the following conditions: Metastatic Colorectal Cancer.

What interventions are being tested in trial NCT05608044?

The interventions under investigation include: Standard of Care (DRUG), Balstilimab (DRUG), Botensilimab (DRUG).

Who is sponsoring clinical trial NCT05608044?

This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05608044 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Colorectal Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.